|
Welcome
|
|
11 February 2012
|
|
|
| home | my details | ISRCTN Register | mRCT | links | information | news |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
|
| [ ...Back to search results ] | [ Print-friendly version ] |
| A randomised, controlled, factorial pilot study investigating omacor and/or fluvastatin in patients with chronic hepatitis C who have not responded to standard combination anti-viral therapy |
| Source of record | UK Trials |
| ISRCTN | ISRCTN48248159 |
| Date ISRCTN assigned | 27/03/2008 |
| Local reference number(s) | EudraCT: 2006-004335-29 |
| Public title | A randomised, controlled, factorial pilot study investigating omacor and/or fluvastatin in patients with chronic hepatitis C who have not responded to standard combination anti-viral therapy |
| Scientific title | |
| Acronym | HCV Lipid Study |
| Disease/condition/study domain | Chronic hepatitis C infection |
| Study hypothesis | Null hypotheses: 1. Omacor (low dose or high dose) treatment will have no effect on hepatitis C viral load 2. Fluvastatin treatment will have no effect on viral load |
| Design/methodology | Randomised open 3 x 2 factorial trial |
| Research ethics review | Ethics approval received from the Fife and Forth Valley Research Ethics Committee on the 9th May 2007 (ref: 07/S0501/21). |
| Countries of trial | United Kingdom |
| Participants - inclusion criteria | 1. Age greater than or equal to 18 years 2. Positive hepatitis C ribonucleic acid (RNA) for more than six months 3. Elevated serum alanine transaminase (ALT) above normal limits for each laboratory 4. Previous lack of sustained virological response (SVR) to treatment with standard combination anti-viral therapy (standard interferon alpha and ribavirin and/or pegylated interferon alpha and ribavirin) 5. No lipid modulating agents for at least three months 6. Negative urine pregnancy test (for women of child bearing potential) documented within the 48 hour period prior to the first dose of test drug Additionally all subjects must ensure adequate contraception during and for one month after treatment. |
| Participants - exclusion criteria | 1. Hepatitis B virus (HBV), hepatitis D virus (HDV) or human immunodeficiency virus (HIV) co-infection 2. A medical condition associated with chronic liver disease other than viral hepatitis, specifically excluding non-alcoholic fatty liver disease by body mass index (BMI) greater than or equal to 30 3. Clinical evidence of decompensated cirrhosis (ascites, portal hypertension with grade 2 oesophageal varices, hepatocellular cancer) 4. Alcohol use in excess of safe limits (28 units per week for men and 21 units per week for women) 5. Unable to conform to study protocol due to alcohol misuse or drug abuse 6. Serum alphafoetoprotein greater than or equal to 100 7. Platelet count less than 60,000 cells per/ml 8. Any research study within previous three months 9. Severe seizure disorder or concurrent phenytoin use 10. Lactation 11. History of muscular toxicity secondary to statins or fibrates 12. Hereditary muscle disorder or family history of hereditary muscle disorder 13. Concurrent anti-coagulant use |
| Patient information material | |
| Anticipated start date | 01/12/2007 |
| Anticipated end date | 30/04/2010 |
| Status of trial | Ongoing |
| Target number of participants | 72 |
| Interventions | Patients will be randomised to either: Group 1: olive oil capsules daily for 12 weeks Group 2: omacor 1 g daily for 12 weeks Group 3: omacor 2 g daily for four weeks increasing to 1 g four times a day (q.d.s.) from weeks 5 - 12 Group 4: fluvastatin 40 mg daily for four weeks, then 80 mg daily from weeks 5 - 12, and olive oil capsules daily for 12 weeks Group 5: omacor 1 g daily for 12 weeks, combined with fluvastatin 40 mg daily for four weeks, then 80 mg daily from weeks 5 - 12 Group 6: omacor 2 g daily for four weeks combined with fluvastatin 40 mg daily for four weeks, then omacor 1 g q.d.s and fluvastatin 80 mg daily from weeks 5 - 12 |
| Primary outcome measure(s) | 1. Fall in ALT from pre-treatment (average of screening and baseline visits) to end of treatment (EOT) 2. Fall in HCV viral load (lipoviroparticle [LVP] = putative infectious virion and/or total HCV RNA) from pre-treatment (average of screening and baseline visits) to EOT |
| Secondary outcome measure(s) | No secondary outcome measures |
| Sources of funding | Medical Research Council (UK) (grant ref: AW-67446; G0502028) |
| Sponsor name | Newcastle upon Tyne Hospitals NHS Foundation Trust (UK) |
| Sponsor details | Research and Development Department 4th Floor, Leazes Wing Royal Victoria Infirmary Queen Victoria Road Newcastle upon Tyne United Kingdom NE1 4LP |
| Sponsor website | http://www.newcastle-hospitals.org.uk/ |
| Contact name | Prof Maggie Bassendine |
| Contact details | Freeman Hospital High Heaton Newcastle upon Tyne United Kingdom NE7 7DN |
| More information | For more up-to-date information please go to the ISRCTN link below. |
| Link to record in ISRCTN Register | ISRCTN48248159 |
| Date last extracted from ISRCTN register | 17/04/2008 |
|
|
|
|
|
| © 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement | |
|
|
|
|